论文部分内容阅读
目的分析炎症相关基因多态性与子宫颈癌发病风险及治疗疗效的关系。方法选取110例子宫颈癌患者作为实验组,另选取110例同期体检健康者作为对照组,分析IL-1B、IL-1RN及TNF-α等炎症相关基因的多态性,并比较其与子宫颈癌的发病风险及其治疗疗效的相关性。结果携带IL-1B-511TT基因型、IL-1B-511CT基因型及IL-1B-511CT/TT基因型的患者发生子宫颈癌的风险较高(P<0.05);携带TNF-α-G/A基因型者子宫颈癌发病率较高(P<0.05);而携带IL-1RN变异型基因1/2与2/2的患者子宫颈癌发生率相对较低(P>0.05),以上基因多态性与子宫颈癌患者的临床疗效无明显相关性。结论 IL-1B-511TT、IL-1B-511CT、IL-1B-511CT/TT及TNF-α-G/A等炎症相关基因的多态性可能提高子宫颈癌的发病率,而IL-1RN变异型基因1/2与2/2可能会降低子宫颈癌的发病率,炎症相关基因多态性与子宫颈癌的临床治疗效果不相关。
Objective To analyze the relationship between inflammation related gene polymorphism and the risk of cervical cancer and its curative effect. Methods One hundred and ten patients with cervical cancer were selected as the experimental group, and 110 healthy subjects were selected as the control group. The polymorphisms of IL-1B, IL-1RN and TNF-α were analyzed and compared with those of cervix The risk of cancer and its therapeutic effect. Results The patients with IL-1B-511TT genotype, IL-1B-511CT genotype and IL-1B-511CT / TT genotype had a higher risk of developing cervical cancer (P <0.05) A genotype had a higher incidence of cervical cancer (P <0.05), while the incidence of cervical cancer was lower in those with 1/2 and 2/2 IL-1RN variant genes (P> 0.05). The above genes Polymorphism and cervical cancer patients no significant correlation between the clinical efficacy. Conclusion The polymorphisms of IL-1B-511TT, IL-1B-511CT, IL-1B-511CT / TT and TNF-α-G / A may increase the incidence of cervical cancer, Genes 1/2 and 2/2 may reduce the incidence of cervical cancer, inflammation-related gene polymorphisms and clinical efficacy of cervical cancer is not related.